What's next for San Diego's biotech scene?; in early trial, drug shrinks tumors in children with brain cancer

The growth is unmistakable: The San Diego biotech industry now routinely ranks third in the nation, behind Boston and the Bay Area. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Biotech is practically in San Diego's DNA. Here's how it got there — and how it might evolve By Jonathan Wosen Crystal Milner/STAT The growth is unmistakable: The San Diego biotech industry now routinely ranks third in the nation, behind Boston and the Bay Area. Read More STAT+: In early trial, drug shrinks tumors in majority of children with most common form of brain cancer By Jason Mast Adobe The results of Day One's brain cancer drug are an early but rare glimmer of progress in a disease that has seen little in the last 30 years. Read More Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity By Jonathan Wosen and Akila Muthukumar Adobe The once-daily pill, known as Olumiant, was approved after clinical trials showed that treated patients regrew much of their lost hair. Read More Sponsor content by NEW YORK CITY ECONOMIC DEVELOPMENT CORPORATION With a $1B public investment, NYC is a life sciences hub. Driven by an unmatched diversity of sciences, abundant lab space, and a robust VC & startup ecosystem, NYC has all the makings of an innovation hub. LifeSci NYC is a $1B city initiative to support the industry and help companies expand and grow. Discover more about life sciences in NYC. Startup gets green light to use Apple Watch to track Parkinson's symptoms By Mario Aguilar Adobe The FDA has cleared an Apple Watch-based system to track tremors and other symptoms of Parkinson's disease. Read More Language barriers keep parents from asking questions about their children's care, study finds By Edward Chen Lane Turner/Boston Globe A new study found young patients and families who aren't proficient in English are less comfortable asking questions about their care. Read More Opinion: Understanding long Covid will take the lived experiences of long haulers By Zeenia Framroze Courtesy Zeenia Framroze Understanding long Covid will require gold-standard research plus the lived experiences of people with it and real-world evidence. Read More Listen: Diverse clinical trials: Why aren't we there yet? By Nicholas St. Fleur Keisha Okafor for STAT In this "Color Code" episode, we explore the barriers to achieving more diverse clinical trials and what needs to be done to topple them. Read More STAT+: Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review By Adam Feuerstein Adobe The drug is the first new therapy approved for ALS in Canada since 2018 and also the first medicine to be approved from Amylyx. Read More Opinion: Lessons from earlier pandemics: Vaccine panel must discuss imprinting among infants and toddlers By Steve Brozak and Richard Marfuggi Adobe Imprinting, seen after the Russian pandemic of 1889 and others, needs to be in the discussion of Covid-19 vaccines for infants and toddlers. Read More Monday, June 13, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser